

## Introduction

A growing body of literature has demonstrated a moderate negative correlation between vitamin D insufficiency and morbidity and mortality from Covid-19 infection<sup>1</sup>. Confounding this is the fact that serum vitamin D levels are also low in comorbidities that also correlate with higher Covid-19 mortality<sup>2,3</sup>.

Vitamin D – and at least 30 other immunoregulatory compounds – is produced in response to ultraviolet B (UVB) light<sup>1</sup>. UVB light is standard of care in several autoimmune diseases, including graft vs. host disease, cutaneous T-cell lymphoma, and psoriasis<sup>4,5,6</sup>. To date, no studies have aimed to determine whether or not UVB phototherapy can improve Covid-19 outcomes<sup>7</sup>.

We hypothesize that improving immunoregulation with UVB phototherapy will reduce disproportionate inflammation during the infection, as well as hypercoagulation that are hallmarks of severe COVID infections<sup>8,9</sup>. To test our hypothesis, we are conducting a placebo-controlled, double-blinded, randomized clinical trial of narrow-band UVB (NB-UVB) light in hospitalized Covid-1.4 patients.



## Adaptive Photoprotection Trial NEW ORLEANS Giacomo Adoncecchi, MS; Frank Lau, MD; John MacMahon; Carmen Castilla, MD; Catherine Powell, MS. LSUHSC, Department of Surgery Section of Plastic & Reconstructive Surgery

	Methods
•	Pilot phase enrolled 30 pat

- itients at a single site and will be followed by an adaptive design up to 300 patients at 10 sites. Inclusion criteria included age over 50, a positive PCR Covid-19
- testing, at least one comorbidity and oxygen saturation below 94.
- Exclusion criteria included required ventilatory support at time of enrollment, light sensitive medications and in-patient vitamin D supplementations.
- Other data such as BMI and blood pressure are also measured.
- The phototherapy is used as an adjunct treatment.
- A visually identical light that emits no UVB is used as placebo.
- A minimum of 25% body surface area is exposed to the UVB light.
- Patients were treated for 8 days and followed-up for 20 days.
- Blood draws are performed on day 1 pre-treatment and on days 3, 5 and 8 post-treatment

## Endpoints

- Primary objective is to demonstrate safety and efficacy by showing improved clinical outcomes.
- Secondary objectives are to demonstrate a decrease in Th1 levels, with an increase in Th2 and Treg T-cells. D-dimer and partial thromboplastin time (PTT) are also measured. Lastly, vitamin D levels are measured to demonstrate the efficacy of NB-UVB in this regard.



